iShares U.S. Healthcare ETF News - July 2026
GSK Wins FDA Approval for Jideytro, Validating $10.6B Nuvalent Deal
The U.S. Food and Drug Administration approved GSK’s Jideytro (zidesamtinib) for adult patients with ROS1-positive advanced non-small cell lung cancer. This...
Johnson & Johnson Enters Robotic Surgery Market with FDA-Authorized OTTAVA System
Johnson & Johnson MedTech received FDA De Novo authorization for its OTTAVA Robotic Surgical System. The technology is the first robotic system integrated...
Eli Lilly acquires AtaiBeckley for $3.8B, targeting depression with psychedelic drugs
Eli Lilly agreed to acquire biopharmaceutical firm AtaiBeckley for up to $3.8 billion. The deal marks Lilly’s first major expansion into the psychedelic drug...
Eli Lilly buys AtaiBeckley for $3.8B, expanding into psychedelic depression treatments
Eli Lilly agreed to acquire clinical-stage AtaiBeckley for up to $3.8 billion. The transaction consists of a $2.8 billion upfront cash payment and up to $1...
Ionis and AstraZeneca Fail Phase 3, Stalling Lucrative Eplontersen Expansion
Ionis Pharmaceuticals (Nasdaq: IONS) and AstraZeneca announced today that their Phase 3 CARDIO-TTRansform trial for eplontersen failed its primary endpoint....
Novartis to acquire Myricx Bio for $1.5B, strengthening cancer therapy pipeline
Novartis signed a definitive agreement to acquire Myricx Bio for up to $1.5 billion. The UK-based preclinical oncology company will receive an upfront cash...
Moderna Surges 10% as FDA Panel Unanimously Backs mRNA Flu Vaccine
An FDA advisory committee voted 16-0 to recommend Moderna's mRNA-based influenza vaccine. This unanimous endorsement signals a high likelihood of full FDA...
CMS launches Medicare GLP-1 Bridge, capping Wegovy and Zepbound at $50
CMS officially launched the Medicare GLP-1 Bridge program on July 1, 2026. Eligible Medicare Part D beneficiaries can now access Wegovy and Zepbound for a...